-
Mashup Score: 45
Surgical resection of pulmonary adenocarcinoma is considered to be curative but progression-free survival (PFS) has remained highly variable. Antitumor immune response may be important, however, the prognostic significance of tumor-infiltrating natural killer (NK) and regulatory T (Treg) lymphocytes is uncertain. Resected pulmonary adenocarcinoma tissues (n = 115) were studied by immunohistochemical detection of NKp46 and FoxP3 positivity to identify NK and Treg cells, respectively. Association of cell densities with clinicopathological features and progression-free survival (PFS) as well as overall survival (OS) were analyzed with a follow-up time of 60 months.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer - 8 day(s) ago
Mesenchymal-epithelial transition factor (MET) pathway dysregulation may occur through various mechanisms including MET overexpression, MET gene amplification, or MET exon 14 skipping (METex14) mutations [1–3]. Dysregulated MET is an established oncogenic driver in non–small cell lung cancer (NSCLC) [1,4–7]. In addition to its role in tumor cells, MET signaling may also modulate immune function leading to suppression of anticancer immune responses and MET overexpression or activation could play a role in tumor immune evasion [8–13].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases - 20 day(s) ago
Lurbinectedin was evaluated in a multicenter, open-label, Basket phase 2 study in nine cohorts of patients with different difficult-to-treat tumor types to establish the proof of concept for clinical development [1–5]. Based on the results observed in a cohort of 105 patients with pretreated small cell lung cancer (SCLC) [1], lurbinectedin was approved first in the United States [6] and later in several other countries worldwide. Furthermore, and based on these same results, the European Society of Medical Oncology (ESMO) and the US National Comprehensive Cancer Network (NCCN) guidelines incorporated lurbinectedin as an option for the second-line treatment of SCLC patients [7,8].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2% to 7% of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international guidelines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
One of the most frequent oncogenic event in non-small cell lung cancer (NSCLC) is a glycine to cysteine substitution in position 12 in the V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene i.e., the KRASG12C mutation, detected in 13 % of the cases [1].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 96Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias - 1 month(s) ago
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death protein–ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) antibodies, have been approved for patients with advanced or recurrent non-small cell lung cancer (NSCLC) [1–9]. However, ICIs often cause immune-related adverse events (irAEs), potentially leading to discontinuation of the treatment. A meta-analysis demonstrated that treatment discontinuation due to irAE may affect the outcome of the patient [10].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 75Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression - 1 month(s) ago
Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death receptor-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibodies, form the standard of care in advanced lung cancer. PD-L1 expression status on tumor (TCs) and immune (ICs) cells, as measured by immunohistochemistry (IHC), is a predictive biomarker of the efficacy of PD-1/PD-L1 blockade therapy [1–3]. Multiple assays have been developed to evaluate PD-L1 expression in conjunction with a particular therapeutic agent. For advanced non-small cell lung cancer (NSCLC), the FDA has approved four assays as companion diagnostics (CDxs), viz., PD-L1 IHC 22C3 pharmDx for pembrolizumab therapy, PD-L1 IHC 28–8 pharmDx for a combination of ipilimumab and nivolumab, VENTANA PD-L1 (SP142) for atezolizumab, and VENTANA PD-L1 (SP263) for cemiplimab.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 124Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer - 2 month(s) ago
Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancer cases [1]. Approximately 20–40 % of patients with lung cancer have brain metastases (BMs) at diagnosis or during their disease course [2,3]. The overall survival (OS) of patients with BMs is poor [4]. BMs worsen patients’ quality of life more than other metastases such as bone and liver metastases [5]. The risk of BMs is higher in epidermal growth factor receptor (EGFR)-mutant NSCLC than in EGFR wild-type NSCLC [6].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 117Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer - 2 month(s) ago
Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancer cases [1]. Approximately 20–40 % of patients with lung cancer have brain metastases (BMs) at diagnosis or during their disease course [2,3]. The overall survival (OS) of patients with BMs is poor [4]. BMs worsen patients’ quality of life more than other metastases such as bone and liver metastases [5]. The risk of BMs is higher in epidermal growth factor receptor (EGFR)-mutant NSCLC than in EGFR wild-type NSCLC [6].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2 % to 7 % of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international guidelines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hematologists1Tweet
In resected NSCLC, the density of tumor infiltrating NK or Treg cells associated with both PFS and OS, detailed in report @LungCaJournal. Will pathologic features like these, after neoadjuvant therapy, eventually help guide treatment decisions? https://t.co/S7vvJlkzMU